Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Combination Therapy

CHMP Recommends BRAFTOVI Combination for First‑Line Treatment of BRAFV600E Colorectal Cancer

Based on Phase 3 BREAKWATER results showing clear survival gains, the application now moves to the European Commission for a final decision later this year.

3 ARTICLES

2mo ago

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

3 ARTICLES

2mo ago

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

6 ARTICLES

3mo ago

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III

16 ARTICLES

4mo ago

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

9 ARTICLES

4mo ago

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

5 ARTICLES

5mo ago

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

6 ARTICLES

5mo ago

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

3 ARTICLES

5mo ago

Gilead’s BIC/LEN HIV Tablet Matches Biktarvy in Phase 3 Switch Trial

13 ARTICLES

6mo ago

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

5 ARTICLES

7mo ago

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

3 ARTICLES

7mo ago

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

4 ARTICLES

7mo ago

Repurposed Drug Pair Shows Preclinical Promise Against Advanced Prostate Cancer

5 ARTICLES

9mo ago

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial

5 ARTICLES

10mo ago

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

10 ARTICLES

10mo ago

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

7 ARTICLES

last yr.

New Triple-Drug Regimen Boosts Survival in PIK3CA-Mutant HR+ HER2- Breast Cancer

Combination Therapy

CHMP Recommends BRAFTOVI Combination for First‑Line Treatment of BRAFV600E Colorectal Cancer

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Gilead’s BIC/LEN HIV Tablet Matches Biktarvy in Phase 3 Switch Trial

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

Never miss stories about

Combination Therapy

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

Repurposed Drug Pair Shows Preclinical Promise Against Advanced Prostate Cancer

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

New Triple-Drug Regimen Boosts Survival in PIK3CA-Mutant HR+ HER2- Breast Cancer

Never miss stories about

Combination Therapy